The company said the decrease was partially due to the impact on its clinical services business unit from the adoption of new revenues recognition standards.
Efforts highlighted at last week's AACR meeting included new efforts to advance gene expression signatures, improve PD-L1 tests, and calculate MSI across tumor types.
The companies will combine their respective technologies to create a biomarker and companion diagnostic development service for pharmaceutical customers.
In the hunt for an antigen in solid tumors that CAR-T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.
The company plans to sell 7.9 million shares of common stock at $16 per share through its initial public offering.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
With RNA sequencing and other data, researchers gauged neoantigen formation, immunoediting, and clonal evolution in non-small cell lung cancers.
The firm said revenues from its precision oncology business increased 98 percent in Q4, driven by higher testing volume and increased revenue per test.
In Science this week: a pair of papers finds cytosine base editors can generate off-target mutations, and more.
Researchers will first compare liquid with tissue-based tumor profiling before implementing it as a way to enroll patients into the targeted drug trials.
The long-running Framingham Heart Study has received a $38 million grant, according to the Boston Globe.
A Stanford University investigation finds that its researchers did not take part in He Jiankui's work to develop gene-edited infants.
Retraction Watch reports that two researchers had both a Science and a Nature paper retracted last week.
In Genome Biology this week: genomic sequencing of milkweed bug, benchmark comparison of single-cell RNA sequencing platforms, and more.